The diseases hepatitis B (HBV) and C (HCV) remain a significant health threat worldwide, causing approximately 1.3 million deaths each year.
Updated: Zealand partners with Roche on its amylin analog in a deal worth up to $5.3B
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS